The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
- 51 Downloads
Introduction: The RENAAL (Reduction of Endpoints in Non-insulin dependent diabetes with the Angiotensin II Antagonist Losartan) study demonstrated that, in hypertensive patients with type 2 diabetes mellitus and nephropathy, treatment with losartan plus conventional antihypertensive therapy (CT) reduced the relative risk of end-stage renal disease (ESRD) by 29% versus placebo over the time span of the study (mean patient follow-up of 3.4 years). The objective of this study was to project the effect of losartan compared with placebo on the lifetime incidence of ESRD and associated costs (from a US healthcare system perspective).
Methods: To estimate lifetime incidence of ESRD, we used a competing risks method to account for the risk of death without ESRD. We estimated the cost ($US, year 2002 values) associated with ESRD by combining the cumulative incidence of ESRD with the lifetime cost associated with ESRD. Total cost was estimated as the sum of the cost associated with ESRD, the cost of losartan study therapy and other costs (non-ESRD/non-losartan) expected for patients with type 2 diabetes. Survival was estimated by weighting the life expectancies with and without ESRD by the cumulative risk of ESRD. Costs and outcomes were discounted by 3% per annum.
Results: We projected a lower lifetime incidence of ESRD for losartan patients (66%) compared with placebo patients (83%). This reduction in ESRD resulted in a decrease in cost associated with ESRD of $US31 803 per patient and a gain of 0.99 life-years per patient (0.70 discounted). After accounting for the cost of losartan and the additional cost associated with greater survival, we projected that treatment with losartan would result in a lifetime net saving of $US24 632 per patient.
Conclusion: Treatment with losartan plus CT in patients with type 2 diabetes and nephropathy reduced the within-trial incidence of ESRD and is projected to result in lifetime reductions in ESRD and associated costs, and increased survival, versus placebo.
KeywordsLosartan Weibull Model Losartan Group ESRD Incidence Losartan Therapy
This study was funded by a research grant from Merck & Co., Inc.
G.W. Carides, E.J. Dasbach, W.F. Keane, W.C. Gerth and C.M. Alexander are employed by, and own stock in, Merck & Co., Inc.
S. Shahinfar was formerly employed by, and currently owns stock in, Merck & Co., Inc.
W.H. Herman has consulted with and received lecture fees from Merck & Co., Inc.
B.M. Brenner has received a research grant and consultancy fees from Merck & Co., Inc.
All authors made substantial contributions to the intellectual content of the paper.
- 2.US Renal Data System. USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002Google Scholar
- 5.US Renal Data System. USRDS 2000 annual data report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000 Jun: 251Google Scholar
- 11.Lawless JF. Statistical models and methods for lifetime data. New York: Wiley, 1982Google Scholar
- 12.Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov EBN, Csaki F, editors. 2nd International Symposium of Information Theory and Control. Budapest: Akademia Kiado, 1973: 267–281Google Scholar
- 13.Wolfe RA, Hirth RA, Port FK, et al. Mortality and costs in the first year of dialysis: a comparison between hemodialysis (HD) and peritoneal dialysis (PD) [abstract]. J Am Soc Nephrol 1998; 9: 241AGoogle Scholar
- 15.Firon B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1993Google Scholar
- 18.US Department of Health and Human Services. Healthy People 2010. 2nd ed. With understanding and irqxoving health and objectives for improving health. 2 vols. Washington, DC: US Government Printing Office, 2000 NovGoogle Scholar
- 19.NHANES III Third National Health and Nutrition Examination Survey, 1988–1994. Hyattsville (MD): National Center for Health Statistics [online]. Available from URL: http://www.cdc.gov/nchs/products/elec_prods/subject/nhanes3.htm [Accessed 2006 Feb]Google Scholar
- 21.Murray L, editor. Physician’s desk reference. 60th ed. Montvale (NJ): Thomson PDR, 2006: 1916Google Scholar